SR 67029i

Drug Profile

SR 67029i

Alternative Names: SB 248424

Latest Information Update: 21 Jan 2008

Price : $50

At a glance

  • Originator Unknown
  • Developer Genzyme Oncology; GlaxoSmithKline
  • Class Antihyperlipidaemics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Hyperlipidaemia

Most Recent Events

  • 05 Jan 2005 No development reported - Preclinical for Hyperlipidaemia in Switzerland (unspecified route)
  • 30 Dec 2004 ILEX Oncology has been acquired by Genzyme Corporation and is now called Genzyme Oncology
  • 08 Aug 2002 Preclinical trials in Hyperlipidaemia in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top